Spectrum Pharma gets 'Hanmi-downs' to boost oncology pipeline
This article was originally published in Scrip
Spectrum Pharmaceuticals, best known perhaps for its development of the targeted anticancer treatment, Zevalin (ibritumomab tiuxetan), has bolstered its oncology pipeline through the acquisition of selected rights to Hanmi Pharmaceuticals’ long-acting granulocyte colony-stimulating factor product SPI-2012 (HM10460A). Spectrum has indicated that there are signs of improved activity in the novel formulation over conventional versions of the drug.
You may also be interested in...
Biosimilars of Amgen's blockbuster Neulasta pose a competitive threat to long-acting GSF Rolontis, but the company has experience with group purchasing and notes that large oncology clinics will make more revenue by providing higher-priced products.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.